Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.61 |
| ▸ | DRD3 | P35462 | 9/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8798032 | 0.87 | DRD2 (0.60) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL13532761 | 0.86 | DRD2 (0.61) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL8797479 | 0.81 | DRD2 (0.56) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL8797503 | 0.81 | DRD2 (0.61) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL8798171 | 0.78 | DRD2 (0.52) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL8797552 | 0.78 | DRD2 (0.58) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL11405931 | 0.76 | SIGMAR1 (0.69) | DRD2DRD3HTR7HTR1AHTR2A | |
| SCHEMBL5180132 | 0.76 | DRD2 (1.00) | DRD2DRD3ADRA1AHRH4HTR7 | |
| SCHEMBL13532764 | 0.76 | PARP1 (0.52) | DRD2DRD3ADRA1AHTR7HTR1A | |
| SCHEMBL11465528 | 0.76 | SIGMAR1 (0.76) | DRD2DRD3ADRA1AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0458201-B1 | 9,9-Bis(perfluoroalkyl)xanthene 9-aryl-9-perfluoroalkylxanthene, monomers and polymers derived therefrom | DU PONT (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | disclosed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | disclosed |
| US-5202446-A | Used in preperation of polyimides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-13 | — | — | US | disclosed |
| US-5153336-A | Chemical intermediates for polyimides; rigid, low dielectric, waterproofing; electronic packaging | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5101004-A | Packaging electronic apparatus | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-31 | — | — | US | disclosed |
| US-5097000-A | Polyimides, packaging for electronic equipment | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0458201-A2 | 9,9-Bis(perfluoroalkyl)xanthene 9-aryl-9-perfluoroalkylxanthene, monomers and polymers derived therefrom | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
| US-5051520-A | Chemical intermediates for polymers such as polyimides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885DRD3 432/4885ADRA1A 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.